About
Keyron is a UK- and US-based, preclinical-stage medical device and technology platform company aimed at a highly effective treatment of metabolic diseases. Keyron's patented ForePass® is an innovative medical device designed to safely reverse type-2 diabetes, as well as NASH, and obesity. The company has already demonstrated a full reversal of insulin resistance in animal studies, and recently published the results in The Lancet EBioMedicine. Keyron has upcoming clinical trials in South America and aims to then carry out further clinical trials in the USA. Its founders, directors, advisors and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company is backed by multiple institutional investors based in the USA and EMEA. Keyron is currently fundraising for a $5m Series A investment round to complete our FIH study. Please contact our CEO, Giorgio Castagneto Gissey ([email protected]) for investment enquiries. Disclaimer: This is not a solicitation of investment.
Technologies
Keywords
Company Information
- Employees7
- Founded2016
Location
103c Camley Street, London, England, United Kingdom, N1C 4
